Clinical Trial Update: Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial assessing the efficacy and safety of oral ACT-539313 in adults with moderate to severe binge eating disorder has completed with posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• ACT-539313 (ACT-539313)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Binge-Eating Disorder | Phase 2 | Status: COMPLETED | Results posted: 2023-03-31